{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:47:34Z","timestamp":1793944054587,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00858-x","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:57:59Z","timestamp":1778306279000},"page":"985-995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-0844","authenticated-orcid":false,"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hautz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"2","key":"858_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"858_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","volume":"8","author":"V Pengo","year":"2010","unstructured":"Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237\u201342. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03674.x.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"858_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","volume":"14","author":"C Belizna","year":"2015","unstructured":"Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev. 2015;14(4):358\u201362. https:\/\/doi.org\/10.1016\/j.autrev.2014.12.006.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"858_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","volume":"112","author":"JH Rand","year":"2008","unstructured":"Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-\u03b22-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687\u201395. https:\/\/doi.org\/10.1182\/blood-2008-03-144204. (Epub 2008 Jun 24).","journal-title":"Blood"},{"issue":"12","key":"858_CR5","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1161\/01.cir.96.12.4380","volume":"96","author":"MH Edwards","year":"1997","unstructured":"Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96(12):4380\u20134. https:\/\/doi.org\/10.1161\/01.cir.96.12.4380.","journal-title":"Circulation"},{"issue":"9","key":"858_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577\u201383. https:\/\/doi.org\/10.1177\/0961203306071872.","journal-title":"Lupus"},{"issue":"6","key":"858_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1177\/1076029618755946","volume":"24","author":"Y Zuo","year":"2018","unstructured":"Zuo Y, Fan J, Sarode R, Zhang S, Makris UE, Karp DR, et al. Identifying additional risk factors for thrombosis and pregnancy morbidities among antiphospholipid antibodies carriers. Clin Appl Thromb Hemost. 2018;24(6):980\u20135. https:\/\/doi.org\/10.1177\/1076029618755946. (Epub 2018 Feb 22).","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"858_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102491","volume":"19","author":"E Kravvariti","year":"2020","unstructured":"Kravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary Antiphospholipid Syndrome: a pilot open-label randomized prospective study. Autoimmun Rev. 2020;19(4):102491. https:\/\/doi.org\/10.1016\/j.autrev.2020.102491. (Epub 2020 Feb 19).","journal-title":"Autoimmun Rev"},{"issue":"1","key":"858_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","volume":"65","author":"E Nuri","year":"2017","unstructured":"Nuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17\u201324. https:\/\/doi.org\/10.1007\/s12026-016-8812-z.","journal-title":"Immunol Res"},{"issue":"10","key":"858_CR10","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/jth.12363","volume":"11","author":"A Schmidt-Tanguy","year":"2013","unstructured":"Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013;11(10):1927\u20139. https:\/\/doi.org\/10.1111\/jth.12363.","journal-title":"J Thromb Haemost"},{"key":"858_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00858-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:45Z","timestamp":1785517665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00858-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00858-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joz\u00e9lio Freire de Carvalho is an Editorial Board member of Rheumatology and Therapy. He was not involved in the selection of peer reviewers for this manuscript or in any editorial decisions. Elizabeth Hautz declares no conflicts of interest. Ricard Cervera declares no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}